17
Views
1
CrossRef citations to date
0
Altmetric
Original Article

Limited Efficacy of Intensified Preparative Regimens and Autologous Transplantation as Salvage Therapy in High Grade Non-Hodgkin's Lymphoma

, , , , , , & show all
Pages 521-528 | Received 04 Apr 2000, Published online: 01 Jul 2009
 

Abstract

Between 9/86 and 6/98, 22 patients with relapsed or refractory high grade lymphoma received intensified preparative therapy and underwent autologous transplantation at a single instituttion. Two intensified preparative regimens were used - cyclophosphamide, etoposide, total body irradition (CY-VP-TBI) (N=17) and cyclophosphamide, BCNU, etoposide (CBV) (N=5). For all patients undergoing autologous transplantation, 5 year events free survival (EFS) were only 18% ± 8%. Treatment related mortality was 14% overall but only 8% in patients receiving G-CSF or GM-CSF. Surveival was significantly inferior to the survival observed in a concurrent series of patients with intermediate grade lymphoma, 34% ± 6%, p <. 05. Using high dose therapy in conjunction with autologous transplantation at the time of relapse may not be a valuable a strategy in high-grade lymphoma as in intermediate grade lymphoma although most studies combine the two disorders. Alternative strategies for the use of transplantation in high grade lymphoma, such as the use of transplantation as consolidation therapy, need to be investigated.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.